Evidence map›Paper›PMID 18303947›Full record

ArticlePLoS biology2008

Caldendrin-Jacob: a protein liaison that couples NMDA receptor signalling to the nucleus.

Daniela C Dieterich, Anna Karpova, Marina Mikhaylova, Irina Zdobnova, Imbritt König, Marco Landwehr, Martin Kreutz, Karl-Heinz Smalla, Karin Richter, Peter Landgraf and 8 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PLoS biology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 98 papers.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 184 citations in OpenAlex.

  1. Article
  2. Review
  3. Caldendrin Is a Repressor of PIEZO2 Channels and Touch Sensation in Mice.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024
    Article
  4. Review
  5. Review
  6. Integration of nuclear CaCellular and molecular life sciences : CMLS · 2023
    Article
  7. Review
  8. Novel therapeutic approaches to target neurodegeneration.British journal of pharmacology · 2023
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Synaptic control of DNA methylation involves activity-dependent degradation of DNMT3A1 in the nucleus.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Article

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

18 authors at 4 institutions in 2 countries.

Daniela C DieterichAG Molecular Mechanisms of Plasticity, Department of Neurochemistry and Molecular Biology, Leibniz-Institute for Neurobiology, Magdeburg, Germany.
Anna Karpova
Marina Mikhaylova
Irina Zdobnova
Imbritt König
Marco Landwehr
Martin Kreutz
Karl-Heinz Smalla
Karin Richter
Peter Landgraf
Carsten Reissner
Tobias M Boeckers
Werner Zuschratter
Christina Spilker
Constanze I Seidenbecher
Craig C Garner
Eckart D Gundelfinger
Michael R Kreutz
Leibniz Institute for Neurobiology · DEOtto-von-Guericke-Universität Magdeburg · DEPalo Alto University · USUniversität Ulm · DE

Funding

SAP97 Isoforms in Trafficking Synaptic GluR1R01DA016758 · NIDA · STANFORD UNIVERSITY · PI GARNER, CRAIG C · 2003 to 2007
$1.6M
NIDA NIH HHS DA016758NIDA NIH HHS R01 DA016758
6 · The paper itself

Abstract

NMDA (N-methyl-D-aspartate) receptors and calcium can exert multiple and very divergent effects within neuronal cells, thereby impacting opposing occurrences such as synaptic plasticity and neuronal degeneration. The neuronal Ca2+ sensor Caldendrin is a postsynaptic density component with high similarity to calmodulin. Jacob, a recently identified Caldendrin binding partner, is a novel protein abundantly expressed in limbic brain and cerebral cortex. Strictly depending upon activation of NMDA-type glutamate receptors, Jacob is recruited to neuronal nuclei, resulting in a rapid stripping of synaptic contacts and in a drastically altered morphology of the dendritic tree. Jacob's nuclear trafficking from distal dendrites crucially requires the classical Importin pathway. Caldendrin binds to Jacob's nuclear localization signal in a Ca2+-dependent manner, thereby controlling Jacob's extranuclear localization by competing with the binding of Importin-alpha to Jacob's nuclear localization signal. This competition requires sustained synapto-dendritic Ca2+ levels, which presumably cannot be achieved by activation of extrasynaptic NMDA receptors, but are confined to Ca2+ microdomains such as postsynaptic spines. Extrasynaptic NMDA receptors, as opposed to their synaptic counterparts, trigger the cAMP response element-binding protein (CREB) shut-off pathway, and cell death. We found that nuclear knockdown of Jacob prevents CREB shut-off after extrasynaptic NMDA receptor activation, whereas its nuclear overexpression induces CREB shut-off without NMDA receptor stimulation. Importantly, nuclear knockdown of Jacob attenuates NMDA-induced loss of synaptic contacts, and neuronal degeneration. This defines a novel mechanism of synapse-to-nucleus communication via a synaptic Ca2+-sensor protein, which links the activity of NMDA receptors to nuclear signalling events involved in modelling synapto-dendritic input and NMDA receptor-induced cellular degeneration.

Indexed as

Signal TransductionAnimalsBase SequenceBlotting, WesternCalcium-Binding ProteinsCell NucleusChromatography, AffinityDNA, ComplementaryDNA PrimersImmunohistochemistryNuclear Localization SignalsProtein BindingRatsReceptors, N-Methyl-D-AspartateTwo-Hybrid System TechniquesCa2+-binding protein-1Calcium-Binding ProteinsDNA, ComplementaryDNA PrimersNuclear Localization SignalsReceptors, N-Methyl-D-Aspartate

Identifiers

PMID18303947
PMCPMC2253627
OpenAlexW2009216216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.